Cargando…
Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225244/ https://www.ncbi.nlm.nih.gov/pubmed/25397498 http://dx.doi.org/10.7448/IAS.17.4.19753 |
_version_ | 1782343469367296000 |
---|---|
author | Parczewski, Milosz Witak-Jedra, Magdalena Maciejewska, Katarzyna Bociaga-Jasik, Monika Skwara, Pawel Garlicki, Aleksander Grzeszczuk, Anna Rogalska, Magdalena Jankowska, Maria Lemanska, Malgorzata Hlebowicz, Maria Baralkiewicz, Grazyna Mozer-Lisewska, Iwona Mazurek, Renata Lojewski, Wladyslaw Grabczewska, Edyta Olczak, Anita Jablonowska, Elzbieta Rymer, Weronika Szymczak, Aleksandra Szetela, Bartosz Gasiorowski, Jacek Knysz, Brygida Urbanska, Anna Leszczyszyn-Pynka, Magdalena |
author_facet | Parczewski, Milosz Witak-Jedra, Magdalena Maciejewska, Katarzyna Bociaga-Jasik, Monika Skwara, Pawel Garlicki, Aleksander Grzeszczuk, Anna Rogalska, Magdalena Jankowska, Maria Lemanska, Malgorzata Hlebowicz, Maria Baralkiewicz, Grazyna Mozer-Lisewska, Iwona Mazurek, Renata Lojewski, Wladyslaw Grabczewska, Edyta Olczak, Anita Jablonowska, Elzbieta Rymer, Weronika Szymczak, Aleksandra Szetela, Bartosz Gasiorowski, Jacek Knysz, Brygida Urbanska, Anna Leszczyszyn-Pynka, Magdalena |
author_sort | Parczewski, Milosz |
collection | PubMed |
description | INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted drug resistance associated mutations (tDRM) frequency trend over time are available from 2010. In this study, we analyze the temporal trends in the spread of tDRM from 2008 to 2013. MATERIALS AND METHODS: Partial pol sequences from 833 antiretroviral treatment-naive individuals of European descent (Polish origin) linked to care in 9 of 17 Polish HIV treatment centres were analyzed. Drug resistance interpretation was performed according to WHO surveillance recommendations, subtyping with REGA genotyping 2.0 tool. Time trends were examined for the frequency of t-DRM across subtypes and transmission groups using logistic regression (R statistical platform, v. 3.1.0). RESULTS: Frequency of tDRM proved stable over time, with mutation frequency change from 11.3% in 2008 to 8.3% in 2013 [OR: 0.91 (95% CI 0.80–1,05), p=0.202] (Figure 1a). Also, no significant differences over time were noted for the subtype B (decrease from 8.4% 2008 to 6.2% in 2013 [OR: 0.94 (95% CI 0.79–1.11), p=0.45] and across non-B variants [change from 22.6% 2008 to 23.1% in 2013, OR: 0.94 (95% CI 0.75–1.19), p=0.62]. When patient groups were stratified according to transmission route, in MSM there was a trend for a NNRTI t-DRM decrease (from 6.8% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.02), p=0.0655, slope −0.74%/year) (Figure 1b), related to the subtype B infected MSM (decrease from 7% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.03), p=0.0662, slope −0.75%/year). Overall tDRM frequency decrease was also noted for the heterosexually infected patients [from 17.6% 2008 to 10.3% in 2013, OR: 0.83 (95% CI 0.67–1.02, p=0.077, slope −2.041%/year)] but did not associate with drug class (Figure 1c). In IDUs, the trends in t-DRM frequency were not significant over time (change from 1.9% in 2008 to 0 in 2013 [OR:1.24 (95% CI 0.73–2.26), p=0.4)]. CONCLUSIONS: The frequency of t-DRM in Poland is generally stable over time. Decrease in the overall tDRM frequency in heterosexual infected cases and NNRTI resistance in subtype B infected MSM may be related to the higher treatment efficacy of current cART. |
format | Online Article Text |
id | pubmed-4225244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-42252442014-11-12 Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland Parczewski, Milosz Witak-Jedra, Magdalena Maciejewska, Katarzyna Bociaga-Jasik, Monika Skwara, Pawel Garlicki, Aleksander Grzeszczuk, Anna Rogalska, Magdalena Jankowska, Maria Lemanska, Malgorzata Hlebowicz, Maria Baralkiewicz, Grazyna Mozer-Lisewska, Iwona Mazurek, Renata Lojewski, Wladyslaw Grabczewska, Edyta Olczak, Anita Jablonowska, Elzbieta Rymer, Weronika Szymczak, Aleksandra Szetela, Bartosz Gasiorowski, Jacek Knysz, Brygida Urbanska, Anna Leszczyszyn-Pynka, Magdalena J Int AIDS Soc Poster Sessions – Abstract P221 INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted drug resistance associated mutations (tDRM) frequency trend over time are available from 2010. In this study, we analyze the temporal trends in the spread of tDRM from 2008 to 2013. MATERIALS AND METHODS: Partial pol sequences from 833 antiretroviral treatment-naive individuals of European descent (Polish origin) linked to care in 9 of 17 Polish HIV treatment centres were analyzed. Drug resistance interpretation was performed according to WHO surveillance recommendations, subtyping with REGA genotyping 2.0 tool. Time trends were examined for the frequency of t-DRM across subtypes and transmission groups using logistic regression (R statistical platform, v. 3.1.0). RESULTS: Frequency of tDRM proved stable over time, with mutation frequency change from 11.3% in 2008 to 8.3% in 2013 [OR: 0.91 (95% CI 0.80–1,05), p=0.202] (Figure 1a). Also, no significant differences over time were noted for the subtype B (decrease from 8.4% 2008 to 6.2% in 2013 [OR: 0.94 (95% CI 0.79–1.11), p=0.45] and across non-B variants [change from 22.6% 2008 to 23.1% in 2013, OR: 0.94 (95% CI 0.75–1.19), p=0.62]. When patient groups were stratified according to transmission route, in MSM there was a trend for a NNRTI t-DRM decrease (from 6.8% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.02), p=0.0655, slope −0.74%/year) (Figure 1b), related to the subtype B infected MSM (decrease from 7% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.03), p=0.0662, slope −0.75%/year). Overall tDRM frequency decrease was also noted for the heterosexually infected patients [from 17.6% 2008 to 10.3% in 2013, OR: 0.83 (95% CI 0.67–1.02, p=0.077, slope −2.041%/year)] but did not associate with drug class (Figure 1c). In IDUs, the trends in t-DRM frequency were not significant over time (change from 1.9% in 2008 to 0 in 2013 [OR:1.24 (95% CI 0.73–2.26), p=0.4)]. CONCLUSIONS: The frequency of t-DRM in Poland is generally stable over time. Decrease in the overall tDRM frequency in heterosexual infected cases and NNRTI resistance in subtype B infected MSM may be related to the higher treatment efficacy of current cART. International AIDS Society 2014-11-02 /pmc/articles/PMC4225244/ /pubmed/25397498 http://dx.doi.org/10.7448/IAS.17.4.19753 Text en © 2014 Parczewski M et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Sessions – Abstract P221 Parczewski, Milosz Witak-Jedra, Magdalena Maciejewska, Katarzyna Bociaga-Jasik, Monika Skwara, Pawel Garlicki, Aleksander Grzeszczuk, Anna Rogalska, Magdalena Jankowska, Maria Lemanska, Malgorzata Hlebowicz, Maria Baralkiewicz, Grazyna Mozer-Lisewska, Iwona Mazurek, Renata Lojewski, Wladyslaw Grabczewska, Edyta Olczak, Anita Jablonowska, Elzbieta Rymer, Weronika Szymczak, Aleksandra Szetela, Bartosz Gasiorowski, Jacek Knysz, Brygida Urbanska, Anna Leszczyszyn-Pynka, Magdalena Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title | Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title_full | Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title_fullStr | Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title_full_unstemmed | Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title_short | Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland |
title_sort | time trends in hiv-1 transmitted drug resistance mutation frequency in poland |
topic | Poster Sessions – Abstract P221 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225244/ https://www.ncbi.nlm.nih.gov/pubmed/25397498 http://dx.doi.org/10.7448/IAS.17.4.19753 |
work_keys_str_mv | AT parczewskimilosz timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT witakjedramagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT maciejewskakatarzyna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT bociagajasikmonika timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT skwarapawel timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT garlickialeksander timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT grzeszczukanna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT rogalskamagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT jankowskamaria timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT lemanskamalgorzata timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT hlebowiczmaria timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT baralkiewiczgrazyna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT mozerlisewskaiwona timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT mazurekrenata timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT lojewskiwladyslaw timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT grabczewskaedyta timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT olczakanita timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT jablonowskaelzbieta timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT rymerweronika timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT szymczakaleksandra timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT szetelabartosz timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT gasiorowskijacek timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT knyszbrygida timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT urbanskaanna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland AT leszczyszynpynkamagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland |